Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.

× No keyword cloud information.

34 in total

1. Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.

Authors: P B Jensen; H Roed; T Skovsgaard; E Friche; L Vindeløv; H H Hansen; M Spang-Thomsen
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

2. Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.

Authors: N Niederle; J Ostermann; W Achterrath; L Lenaz; C G Schmidt
Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333

Review 3. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors: J M Henwood; R N Brogden
Journal: Drugs Date: 1990-03 Impact factor: 9.546

4. Clinical pharmacodynamics of continuous-infusion etoposide.

Authors: A A Miller; C F Stewart; E A Tolley
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

5. Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide.

Authors: G M Mead; J Thompson; J W Sweetenham; R B Buchanan; J M Whitehouse; C J Williams
Journal: Cancer Chemother Pharmacol Date: 1987 Impact factor: 3.333

Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.

1. Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.

2. Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.

Review 3. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

4. Clinical pharmacodynamics of continuous-infusion etoposide.

5. Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide.

6. Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.

7. Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma.

8. A phase I trial of continuous infusion VP16-213 (etoposide).

Review 9. Pharmacokinetic optimisation of treatment with oral etoposide.

10. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer.